Wednesday, December 5, 2012
7:00 a.m. - 9:00 a.m.
Add to Calendar
Tuesday, December 4, 2012 12:00 p.m.
Where Marriott La Jolla
4240 La Jolla Village Dr
La Jolla, California 92037
Biosimilars: Pathway Approved, What Comes Next
When the Affordable Care Act created a pathway for biosimilars to be approved by the FDA, many believed this would change the biotechnology industry as we knew it. Since then the agency has been creating the rules that will govern this new area. Join us for a discussion about the challenges state and federal authorities face in creating a system that will work for both innovator companies and manufacturers of biosimilars, and to learn what the real potential of this segment will be as these products come closer to commercialization.
Geoffrey Eich, Global Biosimilars Strategic Planning & Operations, Amgen
Lisa Haile, Partner and Co-Chair, Life Sciences Sector, DLA Piper
Matthew K. Hudes, U.S. Managing Principal, Biotechnology, Deloitte Consulting LLP
Magda Marquet, Ph.D., Co-Chairman & Founder, Althea Technologies
Planner Ashleigh Berry